Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

785 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, Muñoz M, Bermejo B, Margeli M, Anton A, Kahan Z, Csöszi T, Casas MI, Murillo L, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano A, Calvo L, de la Haba-Rodriguez J, Ramos M, Alvarez I, Garcia-Palomo A, Huang Bartlett C, Koehler M, Caballero R, Corsaro M, Huang X, Garcia-Sáenz JA, Chacón JI, Swift C, Thallinger C, Gil-Gil M. Martin M, et al. Among authors: anton a. Ann Oncol. 2021 Apr;32(4):488-499. doi: 10.1016/j.annonc.2020.12.013. Epub 2020 Dec 29. Ann Oncol. 2021. PMID: 33385521 Free article. Clinical Trial.
Etoposide (E) + epirubicin (E) + cisplatin (P) combination chemotherapy (EEP) in advanced gastric cancer: negative impact on clinical outcome. Spanish Cooperative Group for GI Tumor Therapy (T.T.D.).
Díaz-Rubio E, Jimeno J, Aranda E, Massuti B, Camps C, Cervantes A, Dorta J, Cruz Hernández JJ, Dominguez S, Anton A, et al. Díaz-Rubio E, et al. Among authors: anton a. Ann Oncol. 1992 Dec;3(10):861-3. doi: 10.1093/oxfordjournals.annonc.a058113. Ann Oncol. 1992. PMID: 1286050 Free article. Clinical Trial.
A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.).
Díaz-Rubio E, Jimeno J, Antón A, Aranda E, Sánchez J, Massuti B, Cruz-Hernández J, Carrato A, Martin M, Belón J, et al. Díaz-Rubio E, et al. Among authors: anton a. Am J Clin Oncol. 1992 Feb;15(1):56-60. doi: 10.1097/00000421-199202000-00011. Am J Clin Oncol. 1992. PMID: 1550080 Clinical Trial.
Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: a study of the Spanish Group for Research on Sarcomas (GEIS).
Buesa JM, Fra J, Antón A, López-Pousa A, Martín J, García del Muro J, Escudero P, Casado A, Poveda A. Buesa JM, et al. Among authors: anton a. Ann Oncol. 1998 Jul;9(7):783-5. doi: 10.1023/a:1008243427528. Ann Oncol. 1998. PMID: 9739447 Free article. Clinical Trial. No abstract available.
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS).
Buesa JM, López-Pousa A, Martín J, Antón A, García del Muro J, Bellmunt J, Arranz F, Valentí V, Escudero P, Menéndez D, Casado A, Poveda A. Buesa JM, et al. Among authors: anton a. Ann Oncol. 1998 Aug;9(8):871-6. doi: 10.1023/a:1008474802882. Ann Oncol. 1998. PMID: 9789610 Free article. Clinical Trial.
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
Cardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Cardenal F, et al. Among authors: anton a. J Clin Oncol. 1999 Jan;17(1):12-8. doi: 10.1200/JCO.1999.17.1.12. J Clin Oncol. 1999. PMID: 10458212 Clinical Trial.
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Antón A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J. Tabernero J, et al. Among authors: anton a. Ann Oncol. 2004 Sep;15(9):1358-65. doi: 10.1093/annonc/mdh349. Ann Oncol. 2004. PMID: 15319242 Free article. Clinical Trial.
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M, Adrover E, Rodríguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacón C, Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, López-Vega JM, Muñoz M, Mel JR. Martín M, et al. Among authors: anton a. Ann Oncol. 2006 Aug;17(8):1205-12. doi: 10.1093/annonc/mdl135. Epub 2006 Jun 9. Ann Oncol. 2006. PMID: 16766587 Free article. Clinical Trial.
785 results